Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, PMID: 30030507
Moxetumomab Pasudotox: First Global Approval, PMID: 30357593
Moxetumomab Pasudotox, PMID: 31644208
Moxetumomab pasudotox for the treatment of hairy cell leukemia, PMID: 31045462
Moxetumomab Pasudotox, PMID: 30371998
Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia, PMID: 31099793
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations, PMID: 31134324
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia, PMID: 30917739
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia, PMID: 31298972
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval, PMID: 31594764
Hairy cell leukemia: present and future directions, PMID: 31068044
Deamidation in Moxetumomab Pasudotox Leading to Conformational Change and Immunotoxin Activity Loss, PMID: 32534028
[Hairy cell leukemia], PMID: 31447330
Correction to: Moxetumomab Pasudotox: First Global Approval, PMID: 30612318
Treatment of hairy cell leukemia, PMID: 32893700
Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use, PMID: 34383256
Update on hairy cell leukemia, PMID: 29742076
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox, PMID: 22003067
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia, PMID: 31628266
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia, PMID: 32077130
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia, PMID: 31944549
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up, PMID: 29487070
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia, PMID: 28983018
A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains, PMID: 31676342
Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia, PMID: 28449314
5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox, PMID: 29432154
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys, PMID: 23090886
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial, PMID: 33627164
Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia, PMID: 34030585
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction, PMID: 32959985
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, PMID: 28616864
Collateral Damages by Magic Bullets: Hemolytic Uremic and Capillary Leak Syndromes After Moxetumomab Pasudotox Therapy, PMID: 31233704
An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox, PMID: 27220271
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia, PMID: 22355053
Development of Recombinant Immunotoxins for Hairy Cell Leukemia, PMID: 32756468
Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities, PMID: 33076544
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox, PMID: 34202156
Immunoconjugates in the management of hairy cell leukemia, PMID: 26614902
The pharmacological management of hairy cell leukemia, PMID: 32378970
Critical Issues in the Development of Immunotoxins for Anticancer Therapy, PMID: 31669121
Hairy cell leukemia-new genes, new targets, PMID: 23892906
Hairy Cell Leukemia Treatment Approved, PMID: 30262591
How I manage patients with hairy cell leukaemia, PMID: 28146266
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4), PMID: 29572070
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma, PMID: 31500657
Potential breakthroughs with investigational drugs for hairy cell leukemia, PMID: 26329588
Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation, PMID: 32695104
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant, PMID: 30841702
Novel therapeutic options for relapsed hairy cell leukemia, PMID: 25563425
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia, PMID: 27521873
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms., PMID:38851853
Unusual presentation of gastric cancer during treatment of hairy cell leukemia: Exploring the etiological basis of this rare phenomenon., PMID:38328399
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system., PMID:38100054
Hairy Cell Leukemia: Where Are We in 2023?, PMID:37097545
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial., PMID:37059834
Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials., PMID:36931901
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders., PMID:36620555
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia., PMID:36509740
Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance., PMID:36439497
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia., PMID:36108341
Selecting appropriate therapy for hairy cell leukemia: current state and future prospects based on molecularly defined characterization., PMID:35703589
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib., PMID:35450208
Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances., PMID:35403971
Advances in the Treatment of Hairy Cell Leukemia Variant., PMID:35178674
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors., PMID:35143639
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies., PMID:35015686
Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin., PMID:34976821
[Moxetumomab pasudotox-Third line in Hairy cell leukemia]., PMID:34776118
Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments., PMID:34638774
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues., PMID:34535326
Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use., PMID:34383256
Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies., PMID:34275772
Hairy cell leukemia: a brief update on current knowledge and treatment prospects., PMID:34264896
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox., PMID:34202156
Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia., PMID:34030585
[Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?]., PMID:34023063
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines., PMID:33947938
Expert's views and perspectives: an interview with distinguished investigator Dr. Ira Pastan at the National Cancer Institute at NIH., PMID:33928228
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies., PMID:33807678
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia., PMID:33754642
Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia., PMID:33659114
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial., PMID:33627164
Hairy Cell Leukaemia: From Hairy Beginnings to a BRAF New World., PMID:33190264
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction., PMID:32959985
Treatment of hairy cell leukemia., PMID:32893700
Development of Recombinant Immunotoxins for Hairy Cell Leukemia., PMID:32756468
Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation., PMID:32695104
Deamidation in Moxetumomab Pasudotox Leading to Conformational Change and Immunotoxin Activity Loss., PMID:32534028
The pharmacological management of hairy cell leukemia., PMID:32378970
Hairy Cell Leukaemia., PMID:32297104
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia., PMID:32077130
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia., PMID:31944549
A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains., PMID:31676342
Critical Issues in the Development of Immunotoxins for Anticancer Therapy., PMID:31669121
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia., PMID:31628266
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval., PMID:31594764
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma., PMID:31500657
[Hairy cell leukemia]., PMID:31447330
For research use only. Not for human or drug use.
